ArriVent BioPharma (AVBP) vs Wave Life Sciences (WVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
ArriVent BioPharma (AVBP) has outperformed Wave Life Sciences (WVE) over the past year, losing 14.6% versus a loss of 59.9%. ArriVent BioPharma is the larger company by market cap ($821.5 million vs $616.8 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVBP | WVE |
|---|---|---|
| Share price | $16.66 | $3.13 |
| Market cap | $821.47M | $616.76M |
| 1-day change | -0.77% | -1.88% |
| YTD return | -17.20% | -81.59% |
| 1-year return | -14.61% | -59.92% |
| 5-year return | — | -27.88% |
| EPS (TTM) | $-3.62 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $42.73M |
| Revenue growth (YoY) | — | -60.55% |
| Net income (latest FY) | $-166.31M | $-204.38M |
| Operating margin | — | -504.09% |
| Net margin | — | -478.33% |
| 52-week high | $35.83 | $21.73 |
| 52-week low | $11.36 | $3.04 |
| Distance from 52-week high | -53.50% | -85.60% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +29.41% | +450.16% |
| Average volume | 1.00M | 3.17M |
| Shares outstanding | 49.31M | 197.05M |
| Employees | 77 | 317 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVBP has outperformed WVE by 45.3 percentage points over the past year.
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Healthcare · Biotechnology · 77 employees
About Wave Life Sciences
WVE stock →Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Healthcare · Biotechnology · 317 employees
AVBP vs WVE FAQ
Which is bigger, ArriVent BioPharma or Wave Life Sciences?
ArriVent BioPharma (AVBP) is larger, with a market capitalization of $821.47M compared with $616.76M for Wave Life Sciences (WVE).
Which stock has performed better over the past year, AVBP or WVE?
AVBP returned -14.61% over the past 12 months, compared with -59.92% for WVE (price return, excluding dividends). Past performance does not predict future results.
Are ArriVent BioPharma and Wave Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.